Infections in the immunocompromised host: role of daptomycin
Infections in immunocompromised host are increasing worldwide. Definition of immunocompromised host encompasses a number of different pathologies, such as immune-haematological, oncological, intensivist, in addition to all patients being treated with different monoclonal antibodies and TNF-alfa inhibitors. Daptomycin is a novel lipopeptide antimicrobial drug, its activity against Gram-positive bacteria being rapidly cidal, without phenomenon related to bacterial lysis. Daptmomycin received approval for treatment of complicated skin and skin structures infections, sepsis, and right side endocarditis sustained by S. aureus. This article will focus the role of this new drug in the treatment of severe infections in the immunocompromised host. Clinical cases observed recently will be also presented. 